PT  - JOURNAL ARTICLE
AU  - Fabíola Marques de Carvalho
AU  - Leandro Nascimento Lemos
AU  - Luciane Prioli Ciapina
AU  - Rennan Garcias Moreira
AU  - Alexandra Gerber
AU  - Ana Paula C Guimarães
AU  - Tatiani Fereguetti
AU  - Virgínia Antunes de Andrade Zambelli
AU  - Renata Avila
AU  - Tailah Bernardo de Almeida
AU  - Jheimson da Silva Lima
AU  - Shana Priscila Coutinho Barroso
AU  - Mauro Martins Teixeira
AU  - Renan Pedra Souza
AU  - Cynthia Chester Cardoso
AU  - Renato Santana Aguiar
AU  - Ana Tereza Ribeiro de Vasconcelos
TI  - Prevalence of bacterial pathogens and potential role in COVID-19 severity in patients admitted to intensive care units in Brazil
AID  - 10.1101/2020.12.22.20248501
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.12.22.20248501
4099  - http://medrxiv.org/content/early/2020/12/28/2020.12.22.20248501.short
4100  - http://medrxiv.org/content/early/2020/12/28/2020.12.22.20248501.full
AB  - Secondary bacterial and fungal infections are associated with respiratory viral infections and invasive mechanical ventilation. In Coronavirus disease 2019 (COVID-19), lung injury by SARS-CoV-2 and impaired immune response can provide a favorable environment for microorganism growth and colonization in hospitalized individuals. Recent studies suggest that secondary bacterial pneumonia is a risk factor associated with COVID-19. In Brazil, knowledge about microbiota present in COVID-19 patients is incipient. This work describes the microbiota of 21 COVID-19 patients admitted to intensive care units from two Brazilian centers. We identified respiratory, nosocomial and bacterial pathogens as prevalent microorganisms. Other bacterial opportunistic and commensal species are also represented. Virulence factors of these pathogenic species, metabolic pathways used to evade and modulate immunological processes and the interconnection between bacterial presence and virulence in COVID-19 progression are discussed.Article Summary Line We identified respiratory, nosocomial and bacterial pathogens as prevalent microorganisms in 21 Brazilian COVID-19 patients admitted to Intensive Care Units. Pathogen virulence factors and immune response evasion metabolic pathways are correlated to COVID-19 severity.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe present study was approved by the Ethics Commission from Hospital Naval Marcilio Dias and Hospital Eduardo de Menezes (protocol number 32382820.3.0000.5256 and 31462820.3.0000.5149)Funding StatementThis work was developed under the frameworks of Corona-omica-RJ (FAPERJ = E-26/210.179/2020) and Rede Corona-omica BR MCTI/FINEP (FINEP = 01.20.0029.000462/20, CNPq = 404096/2020-4). A.T.R.V. is supported by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq (303170/2017-4) and FAPERJ (E-26/202.903/20). R.S.A. is supported by CNPQ 312688/2017-2, 439119/2018-9; FAPERJ 202.922/2018 .C.C.C is supported by FAPERJ (E-26/202.791/2019) and S.P.C.B is supported by FAPERJ (E-26/010.000168/20). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained. The present study was approved by the Ethics Commission from Hospital Naval Marcilio Dias and Hospital Eduardo de Menezes (protocol numbers 32382820.3.0000.5256 and 31462820.3.0000.5149).The IRB/oversight body are included in the manuscript.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNGS data generated in our study is publicly available in SRA-NCBI (www.ncbi.nlm.nih.gov/sra), Bioproject accession PRJNA683652.